At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 68 enrolled

Drug / intervention

BMS-986408 +4 moredrug

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05407675

NCT05407675Phase 2Completed

Compare CT.gov

A Phase 1/2 Study of BMS-986408 Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors

Bristol-Myers Squibb·interventional·Posted Jun 7, 2022·Updated Oct 3, 2025

In Brief

A Phase 2 clinical trial evaluating BMS-986408, Nivolumab, and 3 other interventions for Advanced Solid Tumors. Completed, enrolled 68 participants across 18 sites in 5 countries.

Detailed Summary

The primary purpose of this study is to characterize the safety profile of BMS-986408 as monotherapy and in combination with nivolumab or nivolumab and ipilimumab to establish the maximum tolerated dose (MTD). The Recommended Phase 2 Dose (RP2D) that optimizes the pharmacokinetic/pharmacodynamic (PK/PD) relationship of BMS-986408 will also be determined.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsAdvanced Solid Tumors

CountriesCanada, France, Spain, Switzerland, United States

Collaborators--

Timeline

Phase 2CompletedFinished

2023202420252026

First PostedJun 2022

Enrollment StartAug 2022

Primary CompletionAug 2024

Study CompletionJul 2025

TodayJul 2026

First PostedJun 7, 2022

Enrollment StartAug 2, 2022

Primary CompletionAug 22, 2024

Study CompletionJul 24, 2025

TodayJul 2, 2026

Enrollment to primary: 2.1 yearsPosted 4.1 years ago